| Formulary Chapter 6: Endocrine system - Full Chapter
|
| Chapter Links... |
 Blood glucose test meters formulary - Nottingham & Notts CCG |
| Details... |
| 06.04.01.01 |
Oestrogens and HRT |
|
|
|
Oestrogen only HRT tablet (Elleste-Solo, Premarin)
|
Formulary
|
Elleste-Solo®- Estradiol tablet 1mg and 2mg (First choice oral estradiol only product)
Premarin®- Conjugated oestrogens tablet
|
|
|
Oestrogen only HRT patch (Estradot, Evorel, Elleste-Solo)
|
Formulary
|
- Evorel® (cheaper, stocked at SFH)
- Estradot®
- Elleste-Solo® MX
|
|
|
Oestrogel ® (Estradiol gel)
|
Formulary
|
Oestrogel®
|
|
|
Combined continuous HRT tablet (Kliofem, Kliovance, Femoston Conti, Premique low dose)
|
Formulary
|
Kliofem® tablet
Kliovance® tablet (lower strength than Kliofem®)
Femoston®-conti tablets
Premique® tablet discontinued December 2016, now only Premique ® low dose tablet available
|
|
|
Combined continuous HRT patch (Evorel® Conti)
|
Formulary
|
Evorel® Conti patches
No bleed products
|
|
|
Combined cyclical HRT tablet (Elleste-Duet®, Femoston)
|
Formulary
|
Elleste-Duet®- tablet 1mg and 2mg
Femoston® 1/10 and 2/10 tablet
Prempak-C® discontinued January 2017
|
|
|
Combined cyclical HRT patch (Evorel® Sequi)
|
Formulary
|
Evorel® Sequi patches
|
|
|
Tibolone (Livial®)
|
Formulary
|
Tablet
|
 MHRA information on breast cancer risks Feb 2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 06.04.01.01 |
Ethinylestradiol |
|
|
Ethinylestradiol
|
Formulary
|
Tablet 10mcg
Tablet 2mcg for paediatric use - named patient use
|
See unexpectedly expensive medicines list
|
| 06.04.01.01 |
Raloxifene |
|
|
Raloxifene Hydrochloride (Evista®)
|
Formulary
|
Tablet
Amber 2 - Treatment and prevention of osteoporosis
|
NICE quick reference guide on osteoporosis
NICE: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)
NICE: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)
Nottinghamshire osteoporosis treatment guidelines July 2019
|
| .... |
| Non Formulary Items |
Angeliq® (Combined continuous HRT tablet)
|
Non Formulary
|
Contains estradiol 1mg and drospirenone 2mg
|
Link to reviews
|
Bazedoxifene/conjugated oestrogens (Duavive®)
|
Non Formulary
|
- No formal assessment
- Due to be discontinued Decmeber 2019
|
Link to reviews
|
Bedol® (Oestrogen only HRT tablet)
|
Non Formulary
|
|
|
|
Climagest® (Combined cyclical HRT tablet)
|
Non Formulary
|
Discontinued |
|
|
Climaval® (Oestrogen only HRT tablet)
|
Non Formulary
|
Discontinued Jan 2016 |
|
|
Climesse® (Combined continuous HRT tablet)
|
Non Formulary
|
Discontinued |
|
|
Clinorette® (Combined cyclical HRT tablet)
|
Non Formulary
|
Contains same active ingredients as Elleste Duet® (see above). |
|
|
Cyclo-Progynova® (Combined cyclical HRT tablet)
|
Non Formulary
|
|
|
|
Elleste-Duet Conti® (Combined continuous HRT tablet)
|
Non Formulary
|
Contains same active ingredients as Kliofem®- see above (APC July 2011). |
|
|
Estracombi® (Combined cyclical HRT patch)
|
Non Formulary
|
Discontinued |
|
|
Estraderm MX®
(Oestrogen only HRT patch)
|
Non Formulary
|
|
|
|
Estraderm TTS® (Oestrogen only HRT patch)
|
Non Formulary
|
TTS 25 and TTS 100 Discontinued Jan 2012 |
|
|
Estradiol Hemihydrate (Lenzetto® 1.53 mg/spray)
|
Non Formulary
|
transdermal spray
|
|
|
Estradiol implant
|
Non Formulary
|
Discontinued July 2011. See SFH memo July 2011.
Unlicensed 25mg and 50mg implants were available from abroad but do not have satisfactory quality assurance. |
|
|
Femapak®
(Combined cyclical HRT)
|
Non Formulary
|
Discontinued |
|
|
Fematrix® (Oestrogen only HRT patch)
|
Non Formulary
|
Discontinued Aug 2012 |
|
|
FemSeven® (Oestrogen only HRT patch)
|
Non Formulary
|
|
|
|
FemSeven® Conti (Combined continuous HRT patch)
|
Non Formulary
|
|
|
|
FemSeven® Sequi (Combined cyclical HRT patch)
|
Non Formulary
|
|
|
|
FemTab® (Oestrogen only HRT tablet)
|
Non Formulary
|
Discontinued |
|
|
FemTab® Sequi
(Combined cyclical HRT tablet)
|
Non Formulary
|
Discontinued |
|
|
Harmogen®
(Oestrogen only HRT tablet)
|
Non Formulary
|
Discontinued |
|
|
Hormonin®
(Oestrogen only HRT tablet)
|
Non Formulary
|
Discontinued |
|
|
Indivina®
(Combined continuous HRT tablet)
|
Non Formulary
|
|
|
|
Novofem®
(Combined cyclical HRT tablet)
|
Non Formulary
|
Contains same active ingredients as Elleste Duet® (see above). |
|
|
Nuvelle® (Combined cyclical HRT tablet)
|
Non Formulary
|
Discontinued |
|
|
Ovestin®
(Oestrogen only HRT tablet)
|
Non Formulary
|
Discontinued |
|
|
Progynova® (Oestrogen only HRT tablet)
|
Non Formulary
|
APC July 2011 |
|
|
Progynova® TS
(Oestrogen only HRT patch)
|
Non Formulary
|
APC July 2011 |
|
|
Sandrena® (Estradiol gel)
|
Non Formulary
|
Oestrogel® is topical oestrogen gel of choice (see above) |
|
|
Tridestra®
(Combined cyclical HRT tablet)
|
Non Formulary
|
|
|
|
Trisequens®
(Combined cyclical HRT tablet)
|
Non Formulary
|
|
|
|
Zumenon®
(Oestrogen only HRT tablet)
|
Non Formulary
|
|
|
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Grey / Non-Formulary: Medicines, which the Nottinghamshire APC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.
Grey / Non-Formulary (undergoing assessment): Work is ongoing and will be reviewed at a future APC meeting.
Grey / Non-Formulary (no formal assessment): APC has not formally reviewed this medicine or indication because it had never been requested for formulary inclusion. Often used for drugs new to market.
|
|
Medicines which should normally be prescribed by specialists only. eg hospital only.
For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.
|
|
Medicines that should be initiated by a specialist and prescribed by primary care prescribers only under a shared care protocol, once the patient has been stabilised.
Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the Nottinghamshire APC.
|
|
Medicines suitable to be prescribed in primary care / general practice after specialist* recommendation or initiation.
A supporting prescribing guideline may be requested which must have been agreed by the relevant secondary care trust DTCs and approved by the Nottinghamshire APC.
*Specialist is defined by the APC as a clinician who has undertaken an appropriate formal qualification or recognised training programme within the described area of practice
|
|
Primary care/ non specialist may initiate as per APC guideline.
The supporting prescribing guideline must have been agreed by the relevant secondary care trust D&TC(s) and approved by the Nottinghamshire APC.
|
|
Medicines suitable for routine use within primary care.
Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing. |
|
|
|
|
|
